Industry
PrimeVigilance
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
Failure Rate
40.0%
2 terminated/withdrawn out of 5 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
2 recruiting1 with results
Enrollment Performance
Analytics
Phase 2
1(33.3%)
Phase 3
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 2(1)
Phase 3(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT04620239Phase 3Recruiting
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Role: collaborator
NCT06532253Phase 1Recruiting
Long-term Safety Trial with NVDX3
Role: collaborator
NCT05276401Phase 2Terminated
Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
Role: collaborator
NCT03726216Completed
Xydalba Utilization Registry in France
Role: collaborator
NCT03696901Terminated
Xydalba Utilization Registry in Germany
Role: collaborator
All 5 trials loaded